Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

NASDAQ:ONVO opened at $0.40 on Wednesday. Organovo has a 52-week low of $0.32 and a 52-week high of $1.83. The firm has a market cap of $6.93 million, a price-to-earnings ratio of -0.48 and a beta of 0.45. The business’s fifty day moving average is $0.43 and its 200 day moving average is $0.44.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. Equities analysts predict that Organovo will post -0.77 EPS for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.